var data={"title":"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/contributors\" class=\"contributor contributor_credentials\">Franklin D Lowy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1426839635\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to treatment of bacteremia in adults caused by methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) will be reviewed here.</p><p>General issues related to <em>S. aureus</em> bacteremia are discussed further separately. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;</a>.)</p><p>Other issues related to MRSA are discussed further separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-epidemiology\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-prevention-and-control\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-skin-and-soft-tissue-infections\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections&quot;</a>.)</p><p/><p>Issues related to management of patients with infection due to <em>S. aureus</em> with reduced <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> susceptibility are discussed in detail separately. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2131054436\"><span class=\"h1\">GENERAL PRINCIPLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Methicillin resistance in <em>S. aureus</em> is defined as an <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a> minimum inhibitory concentration (MIC) of &ge;4 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/1\" class=\"abstract_t\">1</a>]. <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> minimum inhibitory concentration breakpoints for <em>S. aureus </em>are defined as follows (preferably determined by E-tests): susceptible = MIC &le;2 <span class=\"nowrap\">mcg/mL,</span> intermediate = MIC 4 to 8 <span class=\"nowrap\">mcg/mL,</span> and resistant = MIC &ge;16 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p>Antibiotics for treatment of invasive MRSA infections are summarized in the table (<a href=\"image.htm?imageKey=ID%2F114038\" class=\"graphic graphic_table graphicRef114038 \">table 1</a>). <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> or <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> are the agents of choice for treatment of invasive MRSA infections [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2\" class=\"abstract_t\">2</a>]. The optimal approach to use of other agents with activity against MRSA is uncertain; further study is needed. Considerations in selecting an alternative agent include baseline susceptibility testing prior to antibiotic administration and individual patient circumstances (including the type of infection, underlying comorbidities, and concurrent medications).</p><p>Patients with <em>S. aureus</em> infection due to an isolate with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC &ge;2 <span class=\"nowrap\">mcg/mL</span> may not respond to therapy as well as those with infection due to an isolate with a lower MIC. In such cases, poor clinical response to vancomycin therapy should prompt use of <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> or another agent. (See <a href=\"#H2406416818\" class=\"local\">'Borderline vancomycin susceptibility'</a> below and <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p>Inappropriate drugs for monotherapy of MRSA bacteremia include fluoroquinolones, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, and <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/3-7\" class=\"abstract_t\">3-7</a>].</p><p class=\"headingAnchor\" id=\"H108561660\"><span class=\"h1\">CLINICAL APPROACH</span></p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Bacteremia due to MRSA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of MRSA bacteremia consists of prompt source control (such as removal of implicated vascular catheters <span class=\"nowrap\">and/or</span> drainage of purulent collection if present) and prompt initiation of appropriate antimicrobial therapy. Issues related to antibiotic selection for treatment of MRSA bacteremia are discussed below.</p><p>General issues related to evaluation and management of <em>S. aureus</em> bacteremia and the duration of antibiotic therapy (which depends on the source of infection) are discussed in detail separately. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;</a>.)</p><p>Issues related to treatment of MRSA endocarditis are discussed separately. (See <a href=\"topic.htm?path=antimicrobial-therapy-of-native-valve-endocarditis#H1341667378\" class=\"medical medical_review\">&quot;Antimicrobial therapy of native valve endocarditis&quot;, section on 'Methicillin resistant'</a> and <a href=\"topic.htm?path=antimicrobial-therapy-of-prosthetic-valve-endocarditis#H3\" class=\"medical medical_review\">&quot;Antimicrobial therapy of prosthetic valve endocarditis&quot;, section on 'Staphylococci'</a>.)</p><p class=\"headingAnchor\" id=\"H4167563781\"><span class=\"h3\">Initial antibiotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to empiric treatment of <em>S. aureus</em> bacteremia (prior to the availability of susceptibility data) are discussed separately. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults#H4\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;, section on 'Empiric treatment'</a>.)</p><p>For initial treatment of MRSA bacteremia, we are in agreement with the 2011 guidelines issued by the Infectious Diseases Society of America (IDSA), which recommend <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> or <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> (<a href=\"image.htm?imageKey=ID%2F114038\" class=\"graphic graphic_table graphicRef114038 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2\" class=\"abstract_t\">2</a>]. Vancomycin is the agent for which there is the greatest cumulative clinical experience for the treatment of MRSA bacteremia; it requires serum concentration monitoring, particularly in the setting of renal dysfunction. Daptomycin is an acceptable alternative to vancomycin for treatment of MRSA bacteremia, particularly in the setting of known or suspected high vancomycin minimum inhibitory concentration (MIC; &gt;1 <span class=\"nowrap\">mcg/mL);</span> it is more costly than vancomycin and is associated with myopathy, so it requires serum creatine kinase monitoring [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2,8-11\" class=\"abstract_t\">2,8-11</a>]. In areas where teicoplanin is available, some use it as the drug of choice for initial therapy of <em>S. aureus</em> bacteremia, while others favor its use for patients with intolerance to vancomycin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Further study is needed to determine the optimal approach to use of the relatively new agents with activity against MRSA (eg, <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a>, <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">dalbavancin</a>).</p><p>There is no role for routine use of combination therapy (such as <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> plus <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> or <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>) for treatment of MRSA bacteremia; combination therapy may be useful in the presence of a prosthetic device or for salvage therapy, as discussed below [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2,13\" class=\"abstract_t\">2,13</a>]. Vancomycin combined with gentamicin for treatment of MRSA bacteremia and native valve infective endocarditis has been associated with an increased risk of nephrotoxicity [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/14\" class=\"abstract_t\">14</a>]. Vancomycin combined with rifampin has been associated with hepatic adverse effects, drug interactions, and emergence of resistance [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/15,16\" class=\"abstract_t\">15,16</a>].</p><p>The approach to treatment of <em>S. aureus</em> bacteremia caused by isolates with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC &ge;4 is discussed separately. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin#H3869691427\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;, section on 'Infection due to VISA or VRSA'</a>.)</p><p class=\"headingAnchor\" id=\"H2406416818\"><span class=\"h4\">Borderline vancomycin susceptibility</span></p><p class=\"headingAnchor\" id=\"H463548827\"><span class=\"h5\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> minimum inhibitory concentration breakpoints for <em>S. aureus </em>are summarized above. (See <a href=\"#H2131054436\" class=\"local\">'General principles'</a> above.)</p><p>Some studies suggest a worse clinical outcome associated with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> therapy for infection due to MRSA with vancomycin MIC &ge;2 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/17-23\" class=\"abstract_t\">17-23</a>], while others do not [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/24-27\" class=\"abstract_t\">24-27</a>]. One meta-analysis observed increased mortality among patients with MRSA bacteremia treated with vancomycin when the vancomycin MIC was &ge;2 <span class=\"nowrap\">mcg/mL</span> (by E-test; odds ratio [OR] 1.7, 95% CI 1.3-2.2); increased mortality was not observed in cases with vancomycin MIC &le;1.5 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/21\" class=\"abstract_t\">21</a>]. However, a subsequent meta-analysis of patients with <em>S. aureus </em>bacteremia found no difference in mortality between patients whose isolate had high vancomycin MIC (&ge;1.5 <span class=\"nowrap\">mg/L)</span> and those whose isolate had low vancomycin MIC (&lt;1.5 <span class=\"nowrap\">mg/L)</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/24\" class=\"abstract_t\">24</a>]. In addition, a prospective cohort study including 429 patients with <em>S. aureus</em> bacteremia noted that there was no association between vancomycin MIC and 30- or 90-day mortality [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Clinical failures have been reported in patients without evidence of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> resistance [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/28\" class=\"abstract_t\">28</a>]; some of these failures have occurred in patients with heteroresistant infection (in which subpopulations of organisms have higher vancomycin MICs, although it is uncertain whether heteroresistance is a cause of vancomycin treatment failure) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H1897544320\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Heteroresistance'</a>.)</p><p>There may be other factors (apart from <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC) that contribute to clinical outcome; in one study including 532 patients with <em>S. aureus</em> bacteremia, those with infection due to strains with vancomycin MIC (by E-test) &gt;1.5 <span class=\"nowrap\">mcg/mL</span> had poorer outcomes than those infected with strains with vancomycin MIC &le;1.5 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/22\" class=\"abstract_t\">22</a>]; the outcome was independent of the methicillin susceptibility and whether the patients were treated with vancomycin or a beta-lactam.</p><p class=\"headingAnchor\" id=\"H3878788171\"><span class=\"h5\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, if the <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC approaches the limit of the susceptible range (2 <span class=\"nowrap\">mcg/mL)</span> and there is a poor initial clinical response (eg, persistent bacteremia), vancomycin should be discontinued and therapy switched to <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/30,31\" class=\"abstract_t\">30,31</a>]. However, caution is required when treating <em>S. aureus </em>infection with daptomycin in the setting of vancomycin failure; infrequently, <em>S. aureus</em> non-susceptibility to daptomycin has been observed when the organism has persisted in spite of vancomycin therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/32\" class=\"abstract_t\">32</a>]. Therefore, repeat testing of the <em>S. aureus</em> isolate associated with vancomycin failure should be performed to ensure susceptibility to daptomycin. In addition, breakthrough staphylococcal bacteremia in patients treated with daptomycin may reflect emergence of daptomycin non-susceptibility in the infecting isolate; this possibility should be evaluated by performing susceptibility studies on the breakthrough isolate.</p><p>For patients with infection due to <em>S. aureus</em> isolates approaching the limit of the susceptible range (2 <span class=\"nowrap\">mcg/mL)</span> who are not responsive to or are intolerant of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> and <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, there are several potential alternative agents. In such circumstances, the approach to antibiotic selection is uncertain, and it is unknown whether combination therapy or monotherapy is warranted [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/33,34\" class=\"abstract_t\">33,34</a>].</p><p>Possible combination regimens include [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/33\" class=\"abstract_t\">33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> plus <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> or other beta-lactams [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/35-39\" class=\"abstract_t\">35-39</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> plus <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> or other beta-lactams [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/40,41\" class=\"abstract_t\">40,41</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> plus <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/42\" class=\"abstract_t\">42</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> plus <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/43\" class=\"abstract_t\">43</a>]</p><p/><p>Based on the available data, we favor combination therapy with <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> (dosed at 8 to 10 <span class=\"nowrap\">mg/kg</span> rather than 6 <span class=\"nowrap\">mg/kg</span> intravenously [IV] daily) with <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/35,38\" class=\"abstract_t\">35,38</a>]. This approach is based on a small case series that included 26 patients whose MRSA isolates had diminished daptomycin susceptibility; after persistent bacteremia for a median of 10 days on previous antimicrobial therapy, the median time to clearance of bacteremia was two days [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/38\" class=\"abstract_t\">38</a>]. Another report noted enhanced bactericidal activity in vitro with combination therapy using daptomycin and ceftaroline [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/36\" class=\"abstract_t\">36</a>]. Use of this regimen may be limited by cost.</p><p>Possible monotherapy regimens include <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, and <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/44-46\" class=\"abstract_t\">44-46</a>]. Telavancin monotherapy may prove effective for treatment of MRSA bacteremia (thus far, data are limited); in a phase II trial of telavancin for treatment of bacteremia including 17 patients, cure rates were comparable for telavancin and standard therapy (88 versus 89 percent) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/46,47\" class=\"abstract_t\">46,47</a>]. <a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> and <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a> are long-acting lipoglycopeptides; data on these agents for the treatment of MRSA bacteremia are limited as are data on ceftaroline monotherapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/38,44\" class=\"abstract_t\">38,44</a>]. Linezolid and <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a> are bacteriostatic (<a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, ceftaroline, and telavancin are bactericidal), and toxicity limits prolonged use [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/45\" class=\"abstract_t\">45</a>].</p><p>There is no role for use of <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, or fluoroquinolones for treatment of <em>S. aureus</em> bacteremia.</p><p class=\"headingAnchor\" id=\"H516901901\"><span class=\"h3\">Follow-up cultures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After initiation of treatment for MRSA bacteremia, blood cultures should be repeated to document clearance of bacteremia. Failure to clear bacteremia within 48 hours after initiation of therapy should prompt further evaluation, including evaluation of susceptibility data to ensure appropriate antibiotic selection and dosing as well as clinical evaluation for occult focus of infection that may require drainage or other intervention beyond antimicrobial therapy alone. Persistent foci of infection (such as a deep-seated bone infection, abscess, retained prosthetic device, or endovascular source of infection) should be eliminated if feasible.</p><p class=\"headingAnchor\" id=\"H2810885724\"><span class=\"h3\">Adjustments to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Suspected antibiotic failure as a contributing factor to inadequate clinical response should prompt antibiotic adjustment (increasing the drug dose or switching to an alternative regimen) at or after three to four days of persistent bacteremia [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2,30,31,33,48\" class=\"abstract_t\">2,30,31,33,48</a>]. Others have defined persistent bacteremia as a positive blood culture result &gt;7 days after initiation of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/31,49\" class=\"abstract_t\">31,49</a>]; however, some data suggest that the longer MRSA bacteremia persists, the greater the risk of complications [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/48\" class=\"abstract_t\">48</a>].</p><p>For patients with persistent bacteremia in the setting of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> therapy, the MIC should be reviewed carefully, with antibiotic adjustment if needed. (See <a href=\"#H2406416818\" class=\"local\">'Borderline vancomycin susceptibility'</a> above.)</p><p>Repeated isolation of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate therapy should prompt consideration of infection with a strain of <em>S. aureus</em> with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> that has emerged during therapy, even if the MIC of the original isolate was within the susceptible range [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/17,50-52\" class=\"abstract_t\">17,50-52</a>]. Alternatively, persistent bacteremia may reflect abscess or metastatic infection rather than reduced antibiotic susceptibility. (See <a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">&quot;Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin&quot;</a>.)</p><p>For patients who are not responsive to or are intolerant of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> and <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, there are several potential alternative agents; the approach to antibiotic selection is as discussed above. (See <a href=\"#H3878788171\" class=\"local\">'Clinical approach'</a> above.)</p><p class=\"headingAnchor\" id=\"H1666912120\"><span class=\"h1\">DRUGS WITH ACTIVITY AGAINST MRSA</span></p><p class=\"headingAnchor\" id=\"H2204430327\"><span class=\"h2\">Antibiotics of choice</span></p><p class=\"headingAnchor\" id=\"H1666912127\"><span class=\"h3\">Vancomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> is a bactericidal glycopeptide antibiotic that inhibits cell wall synthesis; it is the antibiotic agent for which there is the greatest cumulative clinical experience for treatment of bacteremia caused by methicillin-resistant <em>S. aureus</em>. Tissue penetration is highly variable and depends on the degree of inflammation [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/53-55\" class=\"abstract_t\">53-55</a>].</p><p><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> has a relatively good safety profile and favorable pharmacokinetics that facilitate convenient administration [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/56,57\" class=\"abstract_t\">56,57</a>]. Dosing is discussed separately. (See <a href=\"topic.htm?path=vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults\" class=\"medical medical_review\">&quot;Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults&quot;</a>.)</p><p><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> kills staphylococci more slowly than do beta-lactam antibiotics in vitro and is clearly inferior to beta-lactams for treatment of methicillin-susceptible <em>S. aureus</em> (MSSA) bacteremia and infective endocarditis [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/19,58-62\" class=\"abstract_t\">19,58-62</a>].</p><p>Alternatives to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> should be considered in the setting of adverse effects due to vancomycin or infection with a pathogen with nonsusceptibility to vancomycin.</p><p class=\"headingAnchor\" id=\"H1666912353\"><span class=\"h3\">Daptomycin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> is a bactericidal cyclic lipopeptide antibiotic that causes depolarization of the bacterial cell membrane [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/63,64\" class=\"abstract_t\">63,64</a>]. Dosing for bloodstream infections (as approved by the US Food and Drug Administration) consists of 6 <span class=\"nowrap\">mg/kg</span> intravenously (IV) once daily; some experts favor doses of 8 to 10 <span class=\"nowrap\">mg/kg</span> IV once daily. These higher doses may be warranted in critically ill patients [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/65,66\" class=\"abstract_t\">65,66</a>].</p><p><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> was demonstrated to be noninferior to an antistaphylococcal penicillin or <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> plus low-dose <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> for treatment of <em>S. aureus</em> bacteremia in a trial including 246 patients with <em>S. aureus</em> bacteremia (89 patients with MRSA bacteremia) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/67\" class=\"abstract_t\">67</a>]. At the time of the trial, the comparator regimen was standard of care; however, synergistic aminoglycosides are no longer routinely used for treatment of <em>S. aureus</em> infection given their association with renal dysfunction. A successful outcome was observed for 44 percent of patients who received daptomycin and 42 percent of patients who received antistaphylococcal penicillin or vancomycin plus low-dose gentamicin (absolute difference 2.4 percent; 95 percent CI -10.2 to 15.1 percent).</p><p><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> should not be used for treatment of MRSA bacteremia associated with pneumonia. (See <a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults#H7\" class=\"medical medical_review\">&quot;Treatment of hospital-acquired and ventilator-associated pneumonia in adults&quot;, section on 'Methicillin-resistant Staphylococcus aureus'</a>.)</p><p>The <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> minimum inhibitory concentration may increase during therapy and may be influenced by prior exposure to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/67\" class=\"abstract_t\">67</a>]. Therefore, daptomycin susceptibility testing must be performed prior to therapy and repeated in the event of positive cultures obtained during therapy, particularly if prolonged therapy is administered <span class=\"nowrap\">and/or</span> there is microbiological evidence of persistent infection during therapy [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Adverse effects associated with <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> include myopathy, peripheral neuropathy, and eosinophilic pneumonia [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Serial measurements of serum creatine kinase should be monitored at least weekly, and daptomycin should be discontinued in patients with symptomatic myopathy and creatine phosphokinase (CPK) &ge;5 times the upper limit of normal (ULN) or in asymptomatic patients with CPK &ge;10 times the ULN.</p><p class=\"headingAnchor\" id=\"H2046100574\"><span class=\"h3\">Teicoplanin (in areas where available)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Teicoplanin is a bacteriostatic glycopeptide with similar spectrum of activity and efficacy as <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/70,71\" class=\"abstract_t\">70,71</a>]. It has a longer half-life than vancomycin and can be administered once daily with more rapid infusion rates than vancomycin. It can also be given intramuscularly.</p><p>Teicoplanin tends to be better tolerated than <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. In one meta-analysis including 1276 patients, the efficacy of teicoplanin and vancomycin was similar, but there were significantly fewer episodes of red man syndrome and other adverse events in patients treated with teicoplanin (14 versus 21 percent) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/70\" class=\"abstract_t\">70</a>]. Another meta-analysis noted a lower risk of nephrotoxicity with teicoplanin than with vancomycin [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Teicoplanin is not available in the United States. In areas where it is available, some favor its use for patients with intolerance to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, while others use it as the drug of choice for initial therapy of gram-positive pathogens [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H943808084\"><span class=\"h2\">Alternative agents</span></p><p class=\"headingAnchor\" id=\"H1792319673\"><span class=\"h3\">Ceftaroline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> is a fifth-generation cephalosporin administered as a prodrug whose active metabolite has bactericidal activity against MRSA and vancomycin-intermediate <em>S. aureus </em>(VISA) as well as some gram-negative pathogens [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/73\" class=\"abstract_t\">73</a>]. Ceftaroline has in vitro activity against staphylococci, with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, or <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/74\" class=\"abstract_t\">74</a>]. Thus far, data for use of ceftaroline for treatment of MRSA bacteremia are limited to small retrospective case series [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/44,75,76\" class=\"abstract_t\">44,75,76</a>]. Prolonged use of ceftaroline has been associated with neutropenia; monitoring of hematologic parameters is warranted for patients taking ceftaroline &gt;7 days [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/77\" class=\"abstract_t\">77</a>].</p><p>Ceftobiprole is a newer drug in the same class as <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>; approval by the US Food and Drug Administration is pending.</p><p class=\"headingAnchor\" id=\"H3653227322\"><span class=\"h3\">Lipoglycopeptides</span></p><p class=\"headingAnchor\" id=\"H697742072\"><span class=\"h4\">Telavancin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">Telavancin</a> is a semisynthetic lipoglycopeptide that inhibits cell wall synthesis and disrupts cell membrane permeability [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/78-82\" class=\"abstract_t\">78-82</a>]. It is bactericidal against MRSA, VISA, and vancomycin-resistant <em>S. aureus</em> (VRSA). It has a half-life of seven to nine hours, permitting once-daily dosing. Telavancin should be avoided in patients at risk for nephrotoxicity. Telavancin has a higher rate of toxicity than <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> (including taste disturbance, nausea, vomiting, and renal dysfunction) and has been associated with teratogenicity.</p><p class=\"headingAnchor\" id=\"H1927770786\"><span class=\"h4\">Dalbavancin and oritavancin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> and <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a><strong> </strong>are long-acting lipoglycopeptides; data on these agents for treatment of MRSA bacteremia are limited [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/38,44\" class=\"abstract_t\">38,44</a>]. </p><p class=\"headingAnchor\" id=\"H1666912654\"><span class=\"h3\">Linezolid and tedizolid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> is a bacteriostatic oxazolidinone that inhibits initiation of protein synthesis at the 50S ribosome [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/83,84\" class=\"abstract_t\">83,84</a>]. This drug class may have enhanced efficacy against strains producing toxins such as Panton-Valentine leukocidin, alpha-hemolysin, and toxic shock syndrome toxin 1 [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/85-87\" class=\"abstract_t\">85-87</a>]. <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">Tedizolid</a> is a newer drug in the same class as linezolid; data on its efficacy for treatment of MRSA bacteremia are limited. Linezolid and tedizolid are bacteriostatic (<a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, and <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> are bactericidal), and toxicity limits prolonged use [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/45\" class=\"abstract_t\">45</a>].</p><p><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> has excellent tissue distribution and may be administered parenterally or orally (<a href=\"image.htm?imageKey=ID%2F114038\" class=\"graphic graphic_table graphicRef114038 \">table 1</a>). Monitoring of blood counts and serum chemistries should be performed at least weekly.</p><p>Among 220 adults with MRSA infection, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> had equivalent clinical cure rates overall (73 percent) and in the subgroup with MRSA bacteremia (56 and 50 percent, respectively) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/88\" class=\"abstract_t\">88</a>]. Linezolid resistance and linezolid failure have been described [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/89-93\" class=\"abstract_t\">89-93</a>].</p><p><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> resistance has been observed among methicillin-resistant <em>S. aureus</em> isolates. The mechanism appears to be via the bacterial <em>cfr</em> gene, which resides in a potentially mobile genetic element [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/93\" class=\"abstract_t\">93</a>]. Clinical outbreaks of linezolid-resistant <em>S. aureus</em> (LRSA) have been described; reduction of linezolid use and infection control measures were associated with termination of the outbreaks [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/92,94\" class=\"abstract_t\">92,94</a>].</p><p>Safety concerns limit the extended use of <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>. Adverse effects include thrombocytopenia, anemia, lactic acidosis, peripheral neuropathy, serotonin toxicity, and ocular toxicity [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/95-97\" class=\"abstract_t\">95-97</a>]. Linezolid can reversibly inhibit monoamine oxidase; when administered with serotonergic agents (particularly selective serotonin reuptake inhibitors), it can induce the serotonin syndrome (<a href=\"image.htm?imageKey=EM%2F64604\" class=\"graphic graphic_table graphicRef64604 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/98,99\" class=\"abstract_t\">98,99</a>]. (See <a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">&quot;Serotonin syndrome (serotonin toxicity)&quot;</a>.)</p><p>Thrombocytopenia appears to occur more frequently with more prolonged therapy and in the setting of end-stage renal disease and typically resolves after discontinuation of the drug [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/95\" class=\"abstract_t\">95</a>]. Peripheral neuropathy and lactic acidosis appear to occur more frequently in the setting of prolonged <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> administration and may not resolve after drug discontinuation [<a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/96,97\" class=\"abstract_t\">96,97</a>].</p><p class=\"headingAnchor\" id=\"H703148598\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-methicillin-resistant-staphylococcus-aureus\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Methicillin-resistant Staphylococcus aureus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) bacteremia consists of prompt source control (such as removal of implicated vascular catheters <span class=\"nowrap\">and/or</span> drainage of purulent collection if present) and prompt initiation of appropriate antimicrobial therapy. (See <a href=\"#H14\" class=\"local\">'Bacteremia due to MRSA'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>General issues related to evaluation and management of <em>S. aureus</em> bacteremia, empiric treatment of <em>S. aureus</em> bacteremia (prior to the availability of susceptibility data), and duration of antibiotic therapy (which depends on the source of infection) are discussed separately. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> or <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> for initial antibiotic management of MRSA bacteremia (<a href=\"image.htm?imageKey=ID%2F114038\" class=\"graphic graphic_table graphicRef114038 \">table 1</a>) (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). Vancomycin is the agent for which there is the greatest cumulative clinical experience for the treatment of MRSA bacteremia; it requires serum concentration monitoring, particularly in the setting of renal dysfunction. Daptomycin is an acceptable alternative to vancomycin for treatment of MRSA bacteremia, particularly in the setting of known or suspected high vancomycin minimum inhibitory concentration (MIC; &gt;1 <span class=\"nowrap\">mcg/mL);</span> it is costlier than vancomycin and is associated with myopathy (so requires serum creatine kinase monitoring). (See <a href=\"#H4167563781\" class=\"local\">'Initial antibiotic therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some studies suggest a worse clinical outcome associated with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> therapy for infection due to MRSA with vancomycin MIC &ge;2 <span class=\"nowrap\">mcg/mL,</span> while others do not. In general, if the vancomycin MIC approaches the limit of the susceptible range (2 <span class=\"nowrap\">mcg/mL)</span> and there is a poor initial clinical response, we suggest that vancomycin be discontinued and therapy switched to <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> (<a href=\"image.htm?imageKey=ID%2F114038\" class=\"graphic graphic_table graphicRef114038 \">table 1</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H2406416818\" class=\"local\">'Borderline vancomycin susceptibility'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MRSA bacteremia may persist in the setting of persistent foci of infection or antibiotic failure. Persistent bacteremia should prompt careful evaluation for persistent foci of infection, such as a deep-seated bone infection, abscess, retained prosthetic device, or endovascular source of infection; these should be eliminated if feasible. (See <a href=\"#H2810885724\" class=\"local\">'Adjustments to therapy'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA 2013.</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/2\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/3\" class=\"nounderline abstract_t\">Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015; 350:h2219.</a></li><li class=\"breakAll\">http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm (Accessed on October 01, 2013).</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/5\" class=\"nounderline abstract_t\">Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/6\" class=\"nounderline abstract_t\">Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/7\" class=\"nounderline abstract_t\">Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11:834.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/8\" class=\"nounderline abstract_t\">Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/9\" class=\"nounderline abstract_t\">Weston A, Golan Y, Holcroft C, Snydman DR. The efficacy of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bloodstream infection in patients with impaired renal function. Clin Infect Dis 2014; 58:1533.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/10\" class=\"nounderline abstract_t\">Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/11\" class=\"nounderline abstract_t\">McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a &beta;-lactam for Staphylococcal bacteremia. Clin Infect Dis 2013; 57:1760.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/12\" class=\"nounderline abstract_t\">Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; :CD007022.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/13\" class=\"nounderline abstract_t\">Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009; 49:1072.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/14\" class=\"nounderline abstract_t\">Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/15\" class=\"nounderline abstract_t\">Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/16\" class=\"nounderline abstract_t\">Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2463.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/17\" class=\"nounderline abstract_t\">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/18\" class=\"nounderline abstract_t\">Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/19\" class=\"nounderline abstract_t\">Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/20\" class=\"nounderline abstract_t\">Soriano A, Marco F, Mart&iacute;nez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/21\" class=\"nounderline abstract_t\">van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/22\" class=\"nounderline abstract_t\">Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/23\" class=\"nounderline abstract_t\">Cervera C, Casta&ntilde;eda X, de la Maria CG, et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis 2014; 58:1668.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/24\" class=\"nounderline abstract_t\">Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 2014; 312:1552.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/25\" class=\"nounderline abstract_t\">Lalueza A, Chaves F, San Juan R, et al. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J Infect Dis 2010; 201:311.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/26\" class=\"nounderline abstract_t\">Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/27\" class=\"nounderline abstract_t\">Baxi SM, Clemenzi-Allen A, Gahbauer A, et al. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2016; 60:5276.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/28\" class=\"nounderline abstract_t\">R&oslash;der BL, Wandall DA, Frimodt-M&oslash;ller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/29\" class=\"nounderline abstract_t\">Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010; 51 Suppl 2:S183.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/30\" class=\"nounderline abstract_t\">Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/31\" class=\"nounderline abstract_t\">Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/32\" class=\"nounderline abstract_t\">van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-na&iuml;ve patient--a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/33\" class=\"nounderline abstract_t\">Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 2016; 71:576.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/34\" class=\"nounderline abstract_t\">Holubar M, Meng L, Deresinski S. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches. Infect Dis Clin North Am 2016; 30:491.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/35\" class=\"nounderline abstract_t\">Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/36\" class=\"nounderline abstract_t\">Werth BJ, Sakoulas G, Rose WE, et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57:66.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/37\" class=\"nounderline abstract_t\">Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother 2015; 70:505.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/38\" class=\"nounderline abstract_t\">Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; 36:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/39\" class=\"nounderline abstract_t\">Mehta S, Singh C, Plata KB, et al. &beta;-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56:6192.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/40\" class=\"nounderline abstract_t\">Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother 2015; 70:311.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/41\" class=\"nounderline abstract_t\">Davis JS, Sud A, O'Sullivan MV, et al. Combination of Vancomycin and &beta;-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Clin Infect Dis 2016; 62:173.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/42\" class=\"nounderline abstract_t\">Claeys KC, Smith JR, Casapao AM, et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2015; 59:1969.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/43\" class=\"nounderline abstract_t\">Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. Open Forum Infect Dis 2014; 1:ofu046.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/44\" class=\"nounderline abstract_t\">Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013; 42:450.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/45\" class=\"nounderline abstract_t\">Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49:395.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/46\" class=\"nounderline abstract_t\">Corey GR, Rubinstein E, Stryjewski ME, et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 2015; 60:787.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/47\" class=\"nounderline abstract_t\">Stryjewski ME, Lentnek A, O'Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014; 14:289.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/48\" class=\"nounderline abstract_t\">Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 2014; 59:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/49\" class=\"nounderline abstract_t\">Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190:1140.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/50\" class=\"nounderline abstract_t\">Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/51\" class=\"nounderline abstract_t\">Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186:661.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/52\" class=\"nounderline abstract_t\">Song JH, Hiramatsu K, Suh JY, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48:4926.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/53\" class=\"nounderline abstract_t\">Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32:1320.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/54\" class=\"nounderline abstract_t\">Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/55\" class=\"nounderline abstract_t\">Alban&egrave;se J, L&eacute;one M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44:1356.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/56\" class=\"nounderline abstract_t\">Choice of antibacterial drugs. Treat Guidel Med Lett 2007; 5:33.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/57\" class=\"nounderline abstract_t\">Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/58\" class=\"nounderline abstract_t\">LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/59\" class=\"nounderline abstract_t\">Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/60\" class=\"nounderline abstract_t\">Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/61\" class=\"nounderline abstract_t\">Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/62\" class=\"nounderline abstract_t\">Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/63\" class=\"nounderline abstract_t\">Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/64\" class=\"nounderline abstract_t\">Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 2013; 26:759.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/65\" class=\"nounderline abstract_t\">Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57:1568.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/66\" class=\"nounderline abstract_t\">Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/67\" class=\"nounderline abstract_t\">Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/68\" class=\"nounderline abstract_t\">Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.</a></li><li class=\"breakAll\">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm (Accessed September 10, 2010).</li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/70\" class=\"nounderline abstract_t\">Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37:209.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/71\" class=\"nounderline abstract_t\">Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005; 55 Suppl 2:ii5.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/72\" class=\"nounderline abstract_t\">Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57:589.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/73\" class=\"nounderline abstract_t\">Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/74\" class=\"nounderline abstract_t\">Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother 2013; 57:3178.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/75\" class=\"nounderline abstract_t\">Vazquez JA, Maggiore CR, Cole P, et al. Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia. Infect Dis Clin Pract (Baltim Md) 2015; 23:39.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/76\" class=\"nounderline abstract_t\">Paladino JA, Jacobs DM, Shields RK, et al. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents 2014; 44:557.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/77\" class=\"nounderline abstract_t\">Furtek KJ, Kubiak DW, Barra M, et al. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother 2016; 71:2010.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/78\" class=\"nounderline abstract_t\">Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/79\" class=\"nounderline abstract_t\">King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53:797.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/80\" class=\"nounderline abstract_t\">Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/81\" class=\"nounderline abstract_t\">Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/82\" class=\"nounderline abstract_t\">Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis 2015; 61 Suppl 2:S58.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/83\" class=\"nounderline abstract_t\">Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/84\" class=\"nounderline abstract_t\">Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/85\" class=\"nounderline abstract_t\">Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/86\" class=\"nounderline abstract_t\">Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/87\" class=\"nounderline abstract_t\">Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/88\" class=\"nounderline abstract_t\">Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/89\" class=\"nounderline abstract_t\">Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/90\" class=\"nounderline abstract_t\">Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003; 22:372.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/91\" class=\"nounderline abstract_t\">Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37:946.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/92\" class=\"nounderline abstract_t\">S&aacute;nchez Garc&iacute;a M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/93\" class=\"nounderline abstract_t\">Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008; 52:2244.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/94\" class=\"nounderline abstract_t\">Bonilla H, Huband MD, Seidel J, et al. Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 2010; 51:796.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/95\" class=\"nounderline abstract_t\">Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/96\" class=\"nounderline abstract_t\">Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/97\" class=\"nounderline abstract_t\">Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/98\" class=\"nounderline abstract_t\">Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.</a></li><li><a href=\"https://www.uptodate.com/contents/methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia/abstract/99\" class=\"nounderline abstract_t\">Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3164 Version 53.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H28\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1426839635\" id=\"outline-link-H1426839635\">INTRODUCTION</a></li><li><a href=\"#H2131054436\" id=\"outline-link-H2131054436\">GENERAL PRINCIPLES</a></li><li><a href=\"#H108561660\" id=\"outline-link-H108561660\">CLINICAL APPROACH</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Bacteremia due to MRSA</a><ul><li><a href=\"#H4167563781\" id=\"outline-link-H4167563781\">- Initial antibiotic therapy</a><ul><li><a href=\"#H2406416818\" id=\"outline-link-H2406416818\">Borderline vancomycin susceptibility</a><ul><li><a href=\"#H463548827\" id=\"outline-link-H463548827\">- General principles</a></li><li><a href=\"#H3878788171\" id=\"outline-link-H3878788171\">- Clinical approach</a></li></ul></li></ul></li><li><a href=\"#H516901901\" id=\"outline-link-H516901901\">- Follow-up cultures</a></li><li><a href=\"#H2810885724\" id=\"outline-link-H2810885724\">- Adjustments to therapy</a></li></ul></li></ul></li><li><a href=\"#H1666912120\" id=\"outline-link-H1666912120\">DRUGS WITH ACTIVITY AGAINST MRSA</a><ul><li><a href=\"#H2204430327\" id=\"outline-link-H2204430327\">Antibiotics of choice</a><ul><li><a href=\"#H1666912127\" id=\"outline-link-H1666912127\">- Vancomycin</a></li><li><a href=\"#H1666912353\" id=\"outline-link-H1666912353\">- Daptomycin</a></li><li><a href=\"#H2046100574\" id=\"outline-link-H2046100574\">- Teicoplanin (in areas where available)</a></li></ul></li><li><a href=\"#H943808084\" id=\"outline-link-H943808084\">Alternative agents</a><ul><li><a href=\"#H1792319673\" id=\"outline-link-H1792319673\">- Ceftaroline</a></li><li><a href=\"#H3653227322\" id=\"outline-link-H3653227322\">- Lipoglycopeptides</a><ul><li><a href=\"#H697742072\" id=\"outline-link-H697742072\">Telavancin</a></li><li><a href=\"#H1927770786\" id=\"outline-link-H1927770786\">Dalbavancin and oritavancin</a></li></ul></li><li><a href=\"#H1666912654\" id=\"outline-link-H1666912654\">- Linezolid and tedizolid</a></li></ul></li></ul></li><li><a href=\"#H703148598\" id=\"outline-link-H703148598\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3164|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/114038\" class=\"graphic graphic_table\">- Antibiotics for treatment of MRSA bacteremia in adults</a></li><li><a href=\"image.htm?imageKey=EM/64604\" class=\"graphic graphic_table\">- Serotonin syndrome drugs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimicrobial-therapy-of-native-valve-endocarditis\" class=\"medical medical_review\">Antimicrobial therapy of native valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antimicrobial-therapy-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Antimicrobial therapy of prosthetic valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">Clinical approach to Staphylococcus aureus bacteremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-epidemiology\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-prevention-and-control\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-skin-and-soft-tissue-infections\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing\" class=\"medical medical_review\">Overview of antibacterial susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serotonin-syndrome-serotonin-toxicity\" class=\"medical medical_review\">Serotonin syndrome (serotonin toxicity)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-methicillin-resistant-staphylococcus-aureus\" class=\"medical medical_society_guidelines\">Society guideline links: Methicillin-resistant Staphylococcus aureus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin\" class=\"medical medical_review\">Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">Treatment of hospital-acquired and ventilator-associated pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults\" class=\"medical medical_review\">Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults</a></li></ul></div></div>","javascript":null}